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Abstract
Background: One of the causes of sensorineural hearing loss (SNHL) is degeneration of the inner hair cells in the
organ of Corti in the cochlea. The SLC17A8 (solute carrier family 17, member 8) gene encodes vesicular glutamate
transporter 3 (VGLUT3), and among its isoforms (VGLUT1-3), only VGLUT3 is expressed selectively in the inner hair
cells (IHCs). VGLUT3 transports the neurotransmitter glutamate into the synaptic vesicles of the IHCs. Mutation of
the SLC17A8 gene is reported to be associated with DFNA25 (deafness, autosomal dominant 25), an autosomal
dominant non-syndromic hearing loss (ADNSHL) in humans.
Methods: In this study, we performed a genetic analysis of 87 unrelated Korean patients with ADNSHL to
determine whether the SLC17A8 gene affects hearing ability in the Korean population.
Results: We found a novel heterozygous frameshift mutation, 2 non-synonymous variations, and a synonymous
variation. The novel frameshift mutation, p.M206Nfs*4, in which methionine is changed to asparagine at amino acid
position 206, resulted in a termination codon at amino acid position 209. This alteration is predicted to encode a
truncated protein lacking transmembrane domains 5 to 12. This mutation is located in a highly conserved region in
VGLUT3 across multiple amino acid alignments in different vertebrate species, but it was not detected in 100
unrelated controls who had normal hearing ability. The results from our study suggest that the p.M206Nfs*4
mutation in the SLC17A8 gene is likely a pathogenic mutation that causes ADNSHL.
Conclusion: Our findings can facilitate the prediction of the primary cause of ADNSHL in Korean patients.
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Background
Hearing loss is a relatively common defect, with an
incidence of 1 to 3 per 1000 births [1, 2]. It can be
classified as sensorineural hearing loss (SNHL), con-
ductive hearing loss, or mixed hearing loss, and the
major cause of hearing loss is attributed to genetic or
environmental factors [3, 4]. SNHL is usually caused
by malfunction or degeneration of the cochlea, in-
cluding the hair cells within the organ of Corti [5, 6].
Approximately 70 % of hereditary SNHL cases are
recognized as non-syndromic, which refers to hearing
loss not accompanied by any clinical signs or symp-
toms [7–9]. Among non-syndromic hearing loss cases,
approximately 75–80 % of cases are defined as auto-
somal recessive (DFNB), 10–20 % as autosomal
dominant (DFNA), 1 % as X-linked, and less than
1 % as mitochondrial inheritance [4, 10]. Autosomal
dominant non-syndromic hearing loss (ADNSHL) is
genetically heterogeneous, and 33 related genes have
been reported to date (http://hereditaryhearinglos-
s.org/). Patients with ADNSHL typically have the
characteristics of a late-onset age, high-frequency sen-
sorineural hearing loss, and progressive worsening
with age [11, 12]. Moreover, the causative gene of
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ADNSHL is considered to be a candidate gene for
presbycusis [11, 13].
The SLC17A8 (solute carrier family 17, member 8) gene
associated with ADNSHL lies within the locus of DFNA25
(MIM: 605583), which is defined to be in the 20-cM re-
gion of chromosome 12q21-24 [11, 13]. The SLC17A8
gene encodes the vesicular glutamate transporter 3
(VGLUT3) protein, which consists of 589 amino acids in
12 exons [13]. This protein is predicted to be composed of
12 transmembrane helices, which are packed in 4 groups
of 3 each [14]. Each transmembrane domain is composed
of 21 amino acids; the region between amino acid posi-
tions 80 and 502 is defined as the major facilitator super-
family (MFS) [15] (http://www.ncbi.nlm.nih.gov/protein/
NP_647480.1). They are single-peptide secondary trans-
porter proteins, which transport diverse hydrophilic sol-
utes [15, 16]. There are 3 VGLUT subtypes (VGLUT1, 2,
and 3), of which only VGLUT3 is expressed in the inner
hair cells (IHCs) [14, 17]. The IHCs are the primary audi-
tory sensory receptors, and glutamate is the essential exci-
tatory neurotransmitter in the IHCs [17–20]. The main
function of VGLUT3 in the IHCs is to transport this
neurotransmitter into vesicles [17]. In the absence of
VGLUT3 expression, the uptake and release of glutamate
are disrupted at the afferent synapses of the IHCs [17–19].
Therefore, mutations in the SLC17A8 gene would result
in the malfunctioning of VGLUT3, which leads to
ADNSHL [13, 17].
To date, only 1 mutation in the SLC17A8 gene,
namely, p.A211V, has been reported, which was in can-
didate family members of Czech and German descent in
the United States [13]. These subjects had progressive,
high-frequency SNHL with an autosomal dominant in-
heritance pattern [13]. Because no such studies on the
SLC17A8 gene in the Asian population have been re-
ported to date, we performed gene screening in 87 unre-
lated Korean ADNSHL candidates and 100 unrelated
Koreans with normal hearing to determine whether this
gene should be considered as a contributing factor to
ADNSHL in the Korean population.
Methods
Subjects and clinical evaluation
For this study, 87 unrelated subjects showing autosomal
dominant inheritance in their pedigrees were recruited
from the Department of Otorhinolaryngology-Head and
Neck Surgery, Kyungpook National University Hospital
in Daegu, Yonsei University Health System Hospital in
Seoul, and Soree Ear Clinic in Seoul, Korea. This cohort
was used in the previous genetic studies [21, 22]; these
previous ones and this study were performed in the
similar period. The hearing levels of the patients were
examined by pure-tone audiometry (PTA). The average
threshold in the PTA was measured at 500, 1000, 2000,
and 4000 Hz in a sound-treated room. For PTA, the
levels of hearing loss are described as follows: ~20 dB is
assigned as normal hearing; 21–40 dB as mild hearing
impairment; 41–70 dB as moderate hearing impairment;
71–95 dB as severe hearing impairment; and >95 dB as
profound hearing impairment [23]. One hundred unre-
lated individuals with normal hearing were recruited
from Kyungpook National University as normal controls.
All the participants provided written informed consent
before the study according to the protocol approved by
the Ethics Committee of Kyungpook National University
Hospital.
Genetic analysis
For genetic analysis, the genomic DNA of the 87 pa-
tients and 100 controls with normal hearing was isolated
from blood samples using FlexiGene DNA kits (Qiagen,
Hilden, Germany). All 12 exons and intron-exon bound-
aries of the SLC17A8 gene (GenBank ID: NM_139319.2)
were amplified by polymerase chain reaction (PCR)
using h-Taq DNA Polymerase (Solgent, Daejeon, Korea).
Primers for each exon for PCR and direct sequencing
were designed to be specific to their regions using
Primer3web version 4.0.0 (http://primer3.ut.ee/). The
amplified PCR products were then purified with exo-
nuclease I (USB, Cleveland, OH, USA) and shrimp alka-
line phosphatase (USB, Cleveland, OH, USA). Purified
PCR products were then sequenced with the BigDye
Terminator version 3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA). The products were
purified by ethanol precipitation and assayed with
3130xl Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). The observed data were analyzed using
Sequencing Analysis version 5.2 (Applied Biosystems,
Foster City, CA, USA) and Chromas Lite version 2.1.1
(Technelysium Pty Ltd., Tewantin, QLD, Australia) soft-
ware. Multiple sequence alignment was performed to
compare the amino acid sequences of different vertebrate
species, including Homo sapiens, Aotus nancymaae, Bos
taurus, Mus musculus, Rattus norvegicus, Xenopus tropi-
calis, and Danio rerio, using CLC Sequence Viewer ver-
sion 6.9 (CLC Bio, Aarhus, Denmark). The novelty of the
newly detected variants was investigated using the dbSNP
database (http://www.ncbi.nlm.nih.gov/snp/) and the 1000
Genomes Project Database (http://www.1000genome-
s.org/) as references. Further prediction of the pathogen-
icity was performed using the Mutation Taster program
(http://www.mutationtaster.org).
Restriction fragment length polymorphism analysis
To confirm whether the variations were present in the
100 normal controls, we performed a restriction frag-
ment length polymorphism (RFLP) analysis. The restric-
tion enzymes FokI (Takara Bio Inc., Otsu, Shiga, Japan)
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and PshAI (New England Biolabs Inc., Beverly, MA,
USA) were chosen using SNP-RFLPing (http://bio.kua-
s.edu.tw/snp-rflping2/rflpUI.jsp) and Webcutter version
2.0 (http://rna.lundberg.gu.se/cutter2/). Each product
was treated with each of the restriction enzymes, and
they were incubated at 37 °C for 1 h to activate the en-
zyme. After 1 h, the products were examined by electro-
phoresis on 2 % agarose gels.
Results
In this study, we screened the SLC17A8 gene in 87 pa-
tients with ADNSHL and identified a novel frameshift
mutation in 1 patient, 2 non-synonymous variations in 2
patients, and a synonymous variation in 18 patients.
These patients with SLC17A8 variations were negative
for other mutations in the previous studies [21, 22].
The SD-38 family consisted of 3 generations, with 8
affected individuals, and the pattern of inheritance was
autosomal dominant (Fig. 1a). The proband (III-2) of
this family was a 47-year-old man with bilateral severe
hearing loss, and a novel frameshift mutation was identi-
fied at nucleotide position 616, where adenine was dupli-
cated (c.616dupA) (Fig. 1b). The corresponding amino
acid sequence produced asparagine at position 206 in-
stead of methionine with a termination codon at amino
acid position 209 (p.M206Nfs*4), which resulted in a
truncated protein. The patient was heterozygous for this
mutation, and no other variations were found at other
exons or intron-exon boundaries. To determine whether
this mutation was pathogenic only for this patient, RFLP
analysis was performed since the mutation destroyed the
FokI site. This variation was not found in the 100 unre-
lated individuals with normal hearing (data not shown).
Moreover, the multiple alignments of the amino acid se-
quence in several vertebrate species revealed that this
amino acid position 206 was highly conserved among
these species (Fig. 1c).
A non-synonymous variation at nucleotide position
232 was detected in the proband (III-1) of the SR-167
family (Fig. 2a). The proband had moderate hearing loss
and the average threshold in the PTA was calculated as
61.7 dB for the right ear and 70 dB for the left ear. This
single-nucleotide change produced guanine at nucleotide
position 232 instead of adenine (c.232A > G) resulting in
an isoleucine to valine (p.I78V) substitution (Fig. 2b).
This variation was reported in the 1000 Genomes Pro-
ject Database (SNP ID: rs141811441) with a global
minor allele frequency (MAF) of 0.1 %. However, it was
predicted to be tolerated (score of 0.59) by SIFT but
probably damaging (score by 0.982) by PolyPhen in the
1000 Genomes Project Database and to be disease caus-
ing by the Mutation Taster program. To verify whether
this variation is pathogenic, the proband’s father (II-2)
was screened. The results confirmed that this variation
was not co-segregated (Fig. 2b). However, the multiple
alignments of amino acid sequences showed that the
amino acid position of this variation was a conserved re-
gion (Fig. 2c).
Another non-synonymous variation was identified at
nucleotide position 1120 in the proband (III-2) of the SR-
357 family (c.1120G > T) (Fig. 3a). This proband had
Fig. 1 Mutation analysis of the SD-38 family with the p.M206Nfs*4
mutation. (a) Pedigree of Korean family SD-38. Squares and circles
represent males and females, respectively. Filled symbols denote
affected individuals, whereas unfilled symbols denote unaffected
individuals. Diagonal lines through the symbols represent deceased
members. The arrow indicates the proband of the SD-38 family.
The individual evaluated in this study is marked with an asterisk.
(b) Partial result of DNA sequencing analysis of the SLC17A8 gene for
the proband (III-2) with p.M206Nfs*4 and a normal control. The wild
type nucleotide sequence at position 616 is compared with that of
the proband (III-2), which shows heterozygous c.616dupA, indicated
with the arrow. (c) Alignment of the VGLUT3 amino acid sequence
in different vertebrate species: Homo sapiens, Aotus nancymaae, Bos
taurus, Mus musculus, Rattus norvegicus, Xenopus tropicalis, and Danio
rerio. The arrow shows the position of the p.M206Nfs*4 mutation
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Fig. 2 Mutation analysis of the SR-167 family with the p.I78V
variation. (a) Pedigree of Korean family SR-167. Squares and circles
denote males and females, respectively. Filled symbols represent
affected individuals, and unfilled symbols represent unaffected
individuals. The individuals evaluated in this study are indicated with
asterisks. The proband of the SR-167 family is marked with an arrow.
(b) Partial result of the DNA sequencing analysis of proband (III-1) ,
her father (II-2) and a normal control. The arrows indicate the position
of c.232A > G. (c) Alignment of the VGLUT3 amino acid sequence in
different vertebrate species: Homo sapiens, Aotus nancymaae, Bos
taurus, Mus musculus, Rattus norvegicus, Xenopus tropicalis, and Danio
rerio. The arrow shows the position of the non-synonymous
variation p.I78V
Fig. 3 Mutation analysis of the SR-357 family with the p.A374S
variation. (a) Pedigree of Korean family SR-357. The filled squares
and the filled circle represent affected males and a female,
respectively. Unfilled symbols denote unaffected individuals. The
symbol with a diagonal line indicates a deceased member. The
individuals evaluated in this study are denoted by asterisks. The
proband of the SR-357 family is indicated with the arrow. (b) Partial
result of the DNA sequencing analysis of proband (III-2) and her
parents (II-3, II-4). The arrows indicate the position of c.1120G > T.
(c) Alignment of the VGLUT3 amino acid sequence in different
vertebrate species: Homo sapiens, Aotus nancymaae, Bos taurus, Mus
musculus, Rattus norvegicus, Xenopus tropicalis, and Danio rerio. The
arrow shows the position of the non-synonymous variation p.A374S
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moderate hearing loss calculated the average threshold in
the PTA as 54.2 dB for the right ear and 45.8 dB for the
left ear. The variation changed guanine to thymine, which
led to an alteration in the amino acid position at 374,
wherein alanine was replaced with serine (p.A374S)
(Fig. 3b). This variation has been described in the 1000
Genomes Project Database (SNP ID: rs138307707) with a
MAF of 0.2 %. Moreover, it has been predicted to be dele-
terious (score of 0.01) by SIFT, probably damaging (score
of 0.999) by PolyPhen, and disease causing by the Muta-
tion Taster program. Therefore, the genes of the proband’s
parents (II-3, II-4) were screened, and the variation was
revealed to be co-segregated from her father (II-3)
(Fig. 3b). The position of this variation, p.A374S, was
highly conserved based on the multiple alignments of
amino acid sequences (Fig. 3c). However, 2 controls with
normal hearing were heterozygous for this variation.
Discussion
Degeneration or loss of function of the cochlea, includ-
ing the IHCs, is an important cause of SNHL [5, 6].
VGLUT3, encoded by the SLC17A8 gene, is expressed
selectively in the IHCs [17]. The function of VGLUT3 is
to transport glutamate into the synaptic vesicles, where
glutamate plays an important role as an excitatory
neurotransmitter [13, 15, 17].
A novel pathogenic mutation, c.616dupA (p.M206Nfs*4),
in the SLC17A8 gene was identified in a patient (III-2) of
the SD-38 family. This mutation not only changed the neu-
tral nonpolar amino acid methionine into the polar amino
acid asparagine but also created a stop codon at amino acid
position 209. According to molecular models, VGLUT3 is
composed of 12 transmembrane helices, and position
M206 is suggested to exist between transmembrane
domains 4 and 5 as a topological domain and is probably
located on the cytoplasmic side [15] (http://www.ncbi.nlm.-
nih.gov/protein/NP_647480.1). Therefore, this mutation
could lead to the loss of the rest of the transmembrane do-
mains (5 to 12), thereby resulting in a truncated protein.
The truncated protein may cause malfunction or dysfunc-
tion of VGLUT3 in the IHCs, thereby leading to SNHL,
but further functional studies are required to elucidate the
effect of the mutation on this protein. Since neither the
1000 Genomes Project Database nor the dbSNP database
had any information on this mutation and since this study
is the first to describe it, we defined it as a novel mutation.
Furthermore, the p.M206Nfs*4 mutation was predicted as
disease causing by the Mutation Taster program. These
results support the theory that the novel p.M206Nfs*4
mutation is more likely to be a pathogenic mutation
causing ADNSHL.
The non-synonymous variation p.I78V in the SR-167
family was not co-segregated from the father (II-2), and
the patient (III-1) may have inherited this variation from
the mother (II-3), who had normal hearing. Because iso-
leucine and valine are neutral nonpolar amino acids, the
molecular structure of the protein may not be disturbed,
and the effect of the amino acid substitution may be
subtle. Therefore, this variation is considered a benign
polymorphism rather than a disease-causing mutation.
The single-nucleotide change in the SR-357 family was
identified at amino acid position 374 (p.A374S). Al-
though this variation was co-segregated from the father
(II-3) to the proband (III-2), we found that the 2 con-
trols with normal hearing were heterozygous for this
variation. Even though a neutral nonpolar amino acid,
alanine, was changed to a polar amino acid, serine, this
residue may be located at the edge of transmembrane
domain 8 and away from the pore according to the mo-
lecular model of VGLUT3 [15], which would have less
influence on the protein structure. Therefore, it is pre-
dicted that the chance of this variation being pathogenic
is relatively low. However, further functional studies will
be required to confirm this hypothesis.
In addition, a synonymous variation, c.171G > A, was
detected with a MAF of 1.03 % in 18 patients out of 87
subjects in this study (data not shown). This variation
has been reported with a MAF of 2.8 % in the 1000 Ge-
nomes Project Database (SNP ID: rs11110359), including
1.4 % in East Asians. Our result of 1.03 % MAF was very
similar to the East Asians.
Conclusions
In summary, this study is the first genetic analysis of
SLC17A8 in patients with ADNSHL in Korea and re-
ports a novel duplication mutation in the SLC17A8 gene.
This study will help in predicting the primary cause of
ADNSHL in Korean patients. In addition, further studies
with more samples are required to improve our under-
standing of the SLC17A8 gene as the major causative
gene for ADNSHL in Korea.
Abbreviations
SNHL: Sensorineural hearing loss; SLC17A8: Solute carrier family 17, member
8; VGLUT3: Vesicular glutamate transporter 3; IHCs: Inner hair cells;
ADNSHL: Autosomal dominant non-syndromic hearing loss; MFS: Major
facilitator superfamily; PTA: Pure-tone audiometry; PCR: Polymerase chain
reaction; RFLP: Restriction fragment length polymorphism; MAF: Minor allele
frequency.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NR performed the experiments and contributed to the writing of the
manuscript. NR, BS, and MAK analyzed the data. UKK, HJP, KYL, and JYC
conceived and designed this study. UKK provided technical advice. UKK
supervised the project and provided critical review of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
Our research was supported by a grant of the Korea Health Technology R&D
Project through the Korea Health Industry Development Institute (KHIDI),
Ryu et al. BMC Medical Genetics  (2016) 17:6 Page 5 of 6
funded by the Ministry of Health & Welfare, Republic of Korea (HI14C2119 to
U.K.K). This work was supported by the National Research Foundation of
Korea (NRF) funded by the Ministry of Science, Information and
Communications Technology (ICT) and Future Planning
(2015R1A2A2A01003438 to U.K.K).
Author details
1Department of Biology, College of Natural Sciences, Kyungpook National
University, Daegu 41566, South Korea. 2Soree Ear Clinics, Seoul 06068, South
Korea. 3School of Life Sciences, BK21 Plus KNU Creative BioResearch Group,
Kyungpook National University, Daegu 41566, South Korea. 4Department of
Otorhinolaryngology-Head and Neck Surgery, School of Medicine,
Kyungpook National University, Daegu 41944, South Korea. 5Department of
Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722,
South Korea.
Received: 26 August 2015 Accepted: 8 January 2016
References
1. Morton NE. Genetic epidemiology of hearing impairment. Ann N Y Acad
Sci. 1991;630:16–31.
2. Morton CC, Nance WE. Newborn hearing screening–a silent revolution. N
Engl J Med. 2006;354(20):2151–64.
3. Morton CC. Genetics, genomics and gene discovery in the auditory system.
Hum Mol Genet. 2002;11(10):1229–40.
4. Smith RJ, Bale Jr JF, White KR. Sensorineural hearing loss in children. Lancet.
2005;365(9462):879–90.
5. Parker MA. Biotechnology in the treatment of sensorineural hearing loss:
foundations and future of hair cell regeneration. J Speech Lang Hear Res.
2011;54(6):1709–31.
6. Nakagawa T. Strategies for developing novel therapeutics for sensorineural
hearing loss. Front Pharmacol. 2014;5:206.
7. ACMG. Genetics Evaluation Guidelines for the Etiologic Diagnosis of
Congenital Hearing Loss. Genetic Evaluation of Congenital Hearing Loss
Expert Panel. ACMG statement. Genet Med. 2002;4(3):162–71.
8. Mahboubi H, Dwabe S, Fradkin M, Kimonis V, Djalilian HR. Genetics of
hearing loss: where are we standing now? Eur Arch Otorhinolaryngol. 2012;
269(7):1733–45.
9. Thirlwall AS, Brown DJ, McMillan PM, Barker SE, Lesperance MM. Phenotypic
characterization of hereditary hearing impairment linked to DFNA25. Arch
Otolaryngol Head Neck Surg. 2003;129(8):830–5.
10. Park MK, Sagong B, Lee JD, Bae SH, Lee B, Choi KS, et al. A1555G
homoplasmic mutation from A1555G heteroplasmic mother with Pendred
syndrome. Int J Pediatr Otorhinolaryngol. 2014;78(11):1996–9.
11. Greene CC, McMillan PM, Barker SE, Kurnool P, Lomax MI, Burmeister M, et
al. DFNA25, a novel locus for dominant nonsyndromic hereditary hearing
impairment, maps to 12q21-24. Am J Hum Genet. 2001;68(1):254–60.
12. Van Camp G, Willems PJ, Smith RJ. Nonsyndromic hearing impairment:
unparalleled heterogeneity. Am J Hum Genet. 1997;60(4):758–64.
13. Ruel J, Emery S, Nouvian R, Bersot T, Amilhon B, Van Rybroek JM, et al.
Impairment of SLC17A8 encoding vesicular glutamate transporter-3,
VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell
dysfunction in null mice. Am J Hum Genet. 2008;83(2):278–92.
14. Fremeau Jr RT, Burman J, Qureshi T, Tran CH, Proctor J, Johnson J, et al. The
identification of vesicular glutamate transporter 3 suggests novel modes of
signaling by glutamate. Proc Natl Acad Sci U S A. 2002;99(22):14488–93.
15. Almqvist J, Huang Y, Laaksonen A, Wang DN, Hovmoller S. Docking and
homology modeling explain inhibition of the human vesicular glutamate
transporters. Protein Sci. 2007;16(9):1819–29.
16. Pao SS, Paulsen IT, Saier Jr MH. Major facilitator superfamily. Microbiol Mol
Biol Rev. 1998;62(1):1–34.
17. Seal RP, Akil O, Yi E, Weber CM, Grant L, Yoo J, et al. Sensorineural deafness
and seizures in mice lacking vesicular glutamate transporter 3. Neuron.
2008;57(2):263–75.
18. Dror AA, Avraham KB. Hearing impairment: a panoply of genes and
functions. Neuron. 2010;68(2):293–308.
19. Stelma F, Bhutta MF. Non-syndromic hereditary sensorineural hearing loss:
review of the genes involved. J Laryngol Otol. 2014;128(1):13–21.
20. Takamori S, Malherbe P, Broger C, Jahn R. Molecular cloning and functional
characterization of human vesicular glutamate transporter 3. EMBO Rep.
2002;3(8):798–803.
21. Kim MA, Kim YR, Sagong B, Cho HJ, Bae JW, Kim J, et al. Genetic analysis of
genes related to tight junction function in the Korean population with non-
syndromic hearing loss. PLoS One. 2014;9(4):e95646.
22. Kim YR, Kim MA, Sagong B, Bae SH, Lee HJ, Kim HJ, et al. Evaluation of the
contribution of the EYA4 and GRHL2 genes in Korean patients with
autosomal dominant non-syndromic hearing loss. PLoS One. 2015;10(3):
e0119443.
23. Lee KY, Choi SY, Bae JW, Kim S, Chung KW, Drayna D, et al. Molecular
analysis of the GJB2, GJB6 and SLC26A4 genes in Korean deafness patients.
Int J Pediatr Otorhinolaryngol. 2008;72(9):1301–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ryu et al. BMC Medical Genetics  (2016) 17:6 Page 6 of 6
